Missed the ITP Australia Virtual Patient Conference for 2022, or would like to revisit one or more of the presentations? View them here.
The PBAC recommends a change for all listings and brands of Rituximab to be added to the Unrestricted Benefits listings.
Leading ITP clinicians come together and deliver consensus guidelines for the treatment of (ITP) in adult patients.
ATAGI recommendation on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised.
A joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca.
ATAGI has released a number of recommendations relating to the COVID-19 Vaccine.
Dr Norman Swan hosts an ABC podcast called ‘Coronacast’, where they talk all things COVID-19. In a recent episode, he talks about the vaccines, the occurrence of blood clots and ITP.
Australian experts confident in AstraZeneca vaccine despite pause in Europe. 7.30 with Leigh Sales (ABC), Dr Norman Swan discussed the the most scrutinised vaccine rollout in history, with the COVID-19 vaccine.
Learn more about our international medical advisor and Paediatric ITP specialist, Michele Lambert as she shares a little about why she’s so passionate about paediatric ITP.
We wanted to get to know each of our ITP Australia Medical Advisory Board members a little more so we caught up with Terry recently to find out a little more about her and why she does the amazing things that she does.
At around this time each year in Australia, many ITP patients ask their primary care professional, whether it’s their GP or haematologist if they should be getting the annual influenza vaccine and there are always varying responses.